Clinical resource
Prostate adenocarcinoma definitive EBRT prostate and pelvic lymph nodes (eviQ ID 3657)
eviQ, Cancer Institute NSW
DoseLab summary
Endorsed eviQ protocol for definitive EBRT to the prostate and pelvic lymph nodes with a simultaneous integrated boost. DoseLab's prostate + pelvic nodes constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each.
Why this is useful
Organ constraints for prostate plus pelvic node treatment at 20, 25 and 39–40 fractions, including bowel bag and large bowel limits from POP-RT.
Reference details
- Title
- Prostate adenocarcinoma definitive EBRT prostate and pelvic lymph nodes (eviQ ID 3657)
- Authors / organization
- eviQ, Cancer Institute NSW
- Publication / protocol
- eviQ Radiation Oncology protocol 3657
- Version
- v.3 — last reviewed 7 November 2024; review due 31 December 2026
- Year
- 2024
- DOI
- Pending verification
- Disease sites
- Prostate
- Topics
- Prostate, Pelvic nodes, Dose Constraints, Protocols
- Fractionation context
- SIB: 60 Gy/20 fx, 68 Gy/25 fx or 78–80 Gy/39–40 fx
- Last reviewed by DoseLab
- 2026-09-22